Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

David-Axel LaplaudRomain CaseyLaetitia BarbinMarc DebouverieJérôme De SèzeDavid BrassatSandrine WiertlewskiBruno BrochetJean PelletierPatrick VermerschGilles EdanChristine Lebrun-FrenayPierre ClavelouEric ThouvenotJean-Philippe CamdessanchéAyman TourbahBruno StankoffAbdullatif Al KhedrPhilippe CabreCatherine LubetzkiCaroline PapeixEric BergerOlivier HeinzlefThomas DebrouckerThibault MoreauOlivier GoutBertrand BourreAbir WahabPierre LabaugeLaurent MagyGilles DeferAnne-Marie GuennocNicolas MaubeugeCéline LabeyrieIvania PatryChantal NifleOlivier CasezLaure MichelFabien RollotEmmanuelle LeraySandra VukusicYohann Fouchernull null

Published in: Neurology (2019)

This study provides Class III evidence that for patients with RRMS, TRF and DMF have similar clinical effectiveness after 2 years of treatment.

Keyphrases

multiple sclerosis
randomized controlled trial
systematic review
white matter